ArticlePloS one2026
Mechanisms of cellular senescence combined with molecular docking strategies: A biomarker study of potential therapeutic targets for allergic rhinitis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBioinformatics and molecular docking methods were used to screen potential biomarkers of cellular senescence in allergic rhinitis (Allergic rhinitis AR), which provided a theoretical basis for revealing the mechanism of AR and exploring new therapeutic approaches.
methodsFour AR-related gene chips (GSE19187, GSE43523, GSE44037, and GSE51392) were downloaded from the gene expression database (GEO) for data pooling. Screening differential genes (DEGs) were taken to intersect with cellular senescence-related genes (SRGs) to obtain differential senescence genes (DESRGs). The differential senescence genes were subjected to Gene Ontology Database (GO) functional analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and GSEA enrichment analysis. Protein-protein interaction (PPI) networks were constructed through the STRING database, MCODE plugin weights were analyzed to identify important gene cluster modules, and Hub genes were screened using the CytoHubba plugin topological network algorithm. Hub gene protein interactions network (GeneMANIA) was constructed by the GeneMANIA database. Predict Hub gene construct mRNA-miNA-lncRNA interactions by miRanda, miRDB, miRWalk, TargetScan, and spongeScan databases; construct Hub gene transcription factor regulatory networks by TRRUST database; analyze Hub gene-drug interactions by DGIdb database and select commonly used drugs in the clinic for molecular docking validation.
resultsA total of 264 differential genes were screened in the training set with corrected P.adj < 0.05 and |log2FC| ≥ 1.2 as the filtering condition, and a total of 866 cellular senescence genes, and 20 differential senescence genes (DESRGs) were obtained by taking the intersection of the two. A total of 19 Hub genes were obtained after PPI analysis, which were CCL2, STAT1, TLR2, IGFBP3, TLR3, KLF4, IL1RN, IRF1, SERPINB2, DPP4, MME, NQO1, SAMHD1, XAF1, PHGDH, EIF4EBP1, CTH, HSPA2, AHR The gene-protein interaction network identified 19 Hub genes associated with 21 functional proteins. 5 of the Hub gene loci were associated with 29 miRNAs and 53 lncRNAs. The transcription factor regulatory network obtained 15 transcription factors capable of regulating Hub genes. The analysis of drug-gene interactions identified 489 drugs that target hub genes. For example, in the case of budesonide, the interacting genes STAT1, TLR2, TLR3, and AHR were selected for molecular docking. Similarly, for mometasone, the interacting genes TLR2 and CTH were chosen for molecular docking.
conclusionMining AR-related Hub senescence genes by bioinformatics analysis, constructing PPI network, ceRNA network, transcription factor regulatory network, gene-drug interaction network and molecular docking validation, we screened 19 CCL2, STAT1, TLR2, IGFBP3, TLR3, KLF4, IL1RN, IRF1, SERPINB2, DPP4, MME, NQO1, SAMHD1, XAF1, PHGDH, EIF4EBP1, CTH, HSPA2, and AHR are expected to be Hub genes for potential diagnostic and therapeutic biomarkers, which will provide targets and new insights for further in-depth explorations of AR cellular senescence-related mechanisms of action and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.